Loading…
Please register to continue your trial period!
meRfi Microbiome provides you with up-to-date, evidence-based insights on the gut microbiota and related health topics.
Access our ever-expanding digital library and get personalized answers through our interactive AI chat platform.
Start your free trial and transform your understanding of the gut microbiota today!
NCT06237452 - RESTORATiVE303 - VE303 & Clostridioides difficile infection (CDI) (recurrent) is a randomized, quadruple-blinded, placebo-controlled phase III prevention trial (parallel assignment) evaluating VE303 in 852 (estimated) patients with primary CDI with high-risk for recurrence population.
Primary outcome measures:
CDI Recurrence Rate at Week 8
The trial is currently recruiting patients.
see also:
NCT03788434 - CONSORTIUM - VE303 & Clostridioides difficile infection (CDI) (recurrent)
…